Notable Bullish Options Activity in Merck (MRK) -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Merck (MRK) Announces New, Updated Data for its KEYTRUDA and Updated Data on LYNPARZA in Multiple Breast Cancer Subtypes to Be Presented at SABCS
November 30, 2017 7:08 AM ESTMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data from six abstracts investigating KEYTRUDA® (pembrolizumab), the companys anti-PD-1 therapy, as both monotherapy and combination therapy, across a range of difficult-to-treat breast cancers, will be presented at the 2017 San Antonio Breast Cancer Symposium (SABCS), Dec. 5 9. In addition to the presentation of KEYTRUDA data at SABCS, updated data on LYNPARZA® (olaparib), the first-in-class poly ADP-ribose polymerase (PARP) inhibitor being co-developed and co-commercialized with AstraZeneca, will be presented.
KEYTRUDA presentations include a Spotlight Session with... More
